Medical Affairs is in the unique position to drive health equity through three main roles: catalyser, capabilities enhancer, and cross-functional collaborator, emphasizing the need for deliberate strategies and actions to close health gaps and improve outcomes for underserved populations.
Through our lens into real-world issues that affect equitable use of industry innovations, Medical Affairs can drive the transformation of industry from a drug-centric perspective to a patient-centric perspective. This article discusses a few of these opportunities.
MAPS speaks with Liz de Somer, CEO of Medicines Australia and Sharon Winton, CEO of Lymphoma Australia to explore patient engagement from the perspectives of industry and patient associations.
By using the framework of Explore, Educate, Embrace we can shape our approach to Health Equity by incorporating it into our daily work.
Events of the last 12 months have driven the pharmaceutical industry to more comprehensively examine how it can address ethnic and racial disparities in health outcomes and clinical research access. It is well accepted that diversity of clinical trial participants is essential to ensure that the trial population is truly representative of the patients who will use the therapy, yet disparities in clinical trial participation remain. A multi-faceted approach is required to understand the critical barriers to clinical research access for patients from diverse backgrounds.
During this thought-provoking webinar, our panel of internationally renowned Patient Advisors and Diversity Experts will share their perspectives on diverse representation in clinical trials and key barriers to research access, and explore solutions to address these critical issues.
This program will: